Vitane Biologics Profile
Key Indicators
- Authorised Capital ₹ 20.00 Cr
as on 26-07-2024
- Paid Up Capital ₹ 18.81 Cr
as on 26-07-2024
- Company Age 18 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 37.70 Cr
as on 26-07-2024
- Revenue -95.88%
(FY 2023)
- Profit 102.88%
(FY 2023)
- Ebitda 99.30%
(FY 2023)
- Net Worth 0.92%
(FY 2023)
- Total Assets 1.35%
(FY 2023)
About Vitane Biologics
The Corporate was formerly known as Epr Centre For Cancer Research & Bioinformatics Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 20.00 Cr and a paid-up capital of Rs 18.81 Cr.
The company has closed loans amounting to ₹37.70 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Vitane Biologics Private Limited India is Ruchita Suryavanshi as COMPANY SECRETARY. Mohammed Sadiq and Mirza Baig serve as directors at the Company.
- CIN/LLPIN
U74999TG2006PTC051463
- Company No.
051463
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Oct 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Medchal, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Vitane Biologics?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ruchita Suryavanshi | Company Secretary | 11-Jul-2024 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mohammed Sadiq  | Director | 30-Mar-2014 | Current |
| Mirza Baig | Director | 30-Mar-2014 | Current |
Financial Performance of Vitane Biologics.
Vitane Biologics Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 95.88% decrease. The company also saw a substantial improvement in profitability, with a 102.88% increase in profit. The company's net worth moved up by a moderate rise of 0.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vitane Biologics?
In 2023, Vitane Biologics had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Vitane Pharmaceuticals Private LimitedActive 18 years 4 monthsMohammed Sadiq, Mirza Baig and 1 more are mutual person
Intracell Therapeutics Private LimitedActive 11 years 10 monthsMohammed Sadiq and Mirza Baig are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 20 Dec 2016 | ₹35.00 Cr | Satisfied |
Karvy Financial Services Limited Creation Date: 02 Oct 2011 | ₹2.70 Cr | Satisfied |
How Many Employees Work at Vitane Biologics?
Vitane Biologics has a workforce of 19 employees as of Jul 25, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vitane Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vitane Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
